Novartis selects French CDMO to make CAR T-cell therapies

By Flora Southey contact

- Last updated on GMT

(Image: Getty/Mumemories)
(Image: Getty/Mumemories)
Cell for Cure will make Novartis’ CAR T-cell treatments in France, in anticipation of Kymriah’s regulatory approval in Europe.

French drugmaker and contract development and manufacturing organisation (CDMO) Cell for Cure has announced it will make chimeric antigen receptor (CAR) T-cell therapies for Novartis at its bioproduction facility in Paris.

According to the agreement, Cell for Cure will employ the same technology and process developed by Novartis at its US-based Morris Plain facility, where the Swiss firm produces Kymriah (tisagenlecleucel) for the US market. Kymriah first received US Food and Drug Administration (FDA) approval in August 2017​ to treat acute lymphoblastic leukaemia (ALL).

Manufacturing of the CAR T-cell therapies – which use a patient’s own modified T-cells to identify and destroy tumour cells – could start in 2019 following a technology transfer to Cell for Cure’s Les Ulis facility.

According to Cell for Cure, once a patient’s T-cells are collected and frozen, they will be “transferred to the Les Ulis site where experts will modify the cells so that they can recognise specific receptors that are part of cancer cells. Following safety and quality testing, the patient’s cells will be infused back into the hospitalised patient.”

The news comes days after the European Medicines Agency (EMA) announced its Committee for Medicinal Products for Human Use (CHMP) had granted positive opinion​ of two CAR T-cell therapies: Novartis’ Kymriah and Kite Pharmaceutical’s Yescarta (axicabtagene ciloleucel).

The European Commission will now review the therapies for regulatory approval across the 28 EU Member States, as well as Norway, Iceland and Liechtenstein.

Cell for Cure’s CDMO business is also responsible for producing Cellectis’ gene-edited ‘off-the-shelf’ CAR T-cell candidates. Last month​, the US Food and Drug Administration (FDA) approved Cellectis’ UCART22 for clinical trials.

Related news

Show more

Related products

show more

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Related suppliers

Follow us


View more